ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper published in Select Science on Advancing Viral Vector Manufacturing

17 Sep 2024 20:31 CEST

September 17th, 2024, Tromsø, Norway - ArcticZymes Technologies (OSE: AZT) has
released a timely whitepaper in Select Science titled "Efficient Chromatin
Removal in Viral Vector Manufacturing Using Salt-Active Nucleases." As global
attention on salt-active nucleases increases, this whitepaper reinforces
ArcticZymes' leadership by offering crucial insights that help viral vector
manufacturers optimize their downstream processing (DSP) and make informed
decisions.

The peer-reviewed studies cited in this paper will help leverage rising interest
about Salt Active Nucleases and guide the spotlight to ArcticZymes' as the
pioneer. This will bring added awareness to products like M-SAN HQ which, these
studies show, demonstrate superior results for viral vector manufacturing,
particularly under physiological salt conditions.

The referenced studies demonstrate how M-SAN HQ efficiently fragments chromatin,
accelerating digestion times and leading to cleaner viral vector products with
fewer DSP steps. These advantages not only increase DSP efficiency and yield but
also significantly reduce costs-crucial benefits for today's fast-growing
therapeutic virus manufacturing sector.

As the tide of interest in salt-active nucleases rises, ArcticZymes is well
-positioned to capitalize, with its cutting-edge enzyme solutions poised to
elevate the company's influence in the evolving bioprocessing landscape.

Commenting on the release, Michael B. Akoh, CEO of ArcticZymes Technologies,
said: "The increasing focus on salt-active nucleases offers a significant
opportunity for ArcticZymes to showcase our leadership in the field. This
whitepaper underscores how our innovative solutions, such as M-SAN HQ, can
revolutionize viral vector manufacturing, helping our partners lower costs and
scale their operations more efficiently. At ArcticZymes, we understand that
bioprocessing is complex, and a 'one size fits all' approach doesn't work.
That's why we've created two specialized nucleases-M-SAN HQ for physiological
salt conditions and SAN HQ GMP for high salt environments. Together, these
enzymes deliver a complete solution for the entire viral vector production
process."

To view the full white paper as published in Select Science click here:
https://cdn.prod.website
-files.com/64d5ee31f6ef966121388e81/66e9a2fcf995c33cd0554eb3_SAN%20Paper%20A4%20
2
024-09.pdf

For more information, please contact:

ArcticZymes Technologies ASA

CEO, Michael B. Akoh Tel: +46 (0) 70 262 37 15

CFO, Børge Sørvoll Tel: +47 95 29 01 87

ir@arcticzymes.com

About ArcticZymes Technologies ASA:

ArcticZymes Technologies ASA (OSE: AZT) is a global leader in supplying best-in
-class enzyme technologies to commercial partners who developing therapeutics,
in vitro diagnostics, and molecular research kit products. Our mission is to
make our customer's lives easier by unlocking new solutions to enhance quality
of life and create a more sustainable, healthy world.

More information:
Access the news on Oslo Bors NewsWeb site

627994_PR_SAN_White_paper_Sep_17.pdf